Cytokinetics, Incorporated
CYTK
Kedudukan dalam Saham
#2300
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Harga Saham
$62.31
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$8.66B
Perubahan (1 hari)
-2.51%
Perubahan (1 tahun)
6.63%
Negara
US
Perdagangan Cytokinetics, Incorporated (CYTK)
Kategori
Healthcare
Margin Operasi untuk Cytokinetics, Incorporated (CYTK)
Margin Operasi pada October 2026 TTM: -992.98%
Menurut laporan kewangan dan harga saham terkini Cytokinetics, Incorporated, margin operasi semasa (TTM) ialah -992.98%. Pada akhir 2023, margin operasi syarikat ialah -6,589.71%.
Sejarah Margin Operasi untuk Cytokinetics, Incorporated dari 2000 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | -992.98% | -65.79% |
| 2024 | -2,902.72% | -55.95% |
| 2023 | -6,589.71% | 1,822.60% |
| 2022 | -342.75% | 29.56% |
| 2021 | -264.54% | 57.21% |
| 2020 | -168.27% | -54.27% |
| 2019 | -367.97% | 30.37% |
| 2018 | -282.26% | -66.72% |
| 2017 | -848.26% | -4,930.64% |
| 2016 | 17.56% | -113.45% |
| 2015 | -130.53% | 315.30% |
| 2014 | -31.43% | -71.58% |
| 2013 | -110.59% | -78.62% |
| 2012 | -517.29% | -56.86% |
| 2011 | -1,199.10% | -37.74% |
| 2010 | -1,926.08% | -6,119.00% |
| 2009 | 32.00% | -106.73% |
| 2008 | -475.68% | 14.71% |
| 2007 | -414.67% | -78.86% |
| 2006 | -1,961.56% | 291.67% |
| 2005 | -500.82% | 75.16% |
| 2004 | -285.92% | -7.20% |
| 2003 | -308.12% | 46.42% |
| 2002 | -210.43% | -3.14% |
| 2001 | -217.25% | 0.00% |
| 2000 | 0.00% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.03% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.